Introduction
============

Intravenous patient-controlled analgesia (IV-PCA) with opioids is the most commonly utilized method for acute postoperative pain management after a major operation because opioids are appropriate for controlling severe pain due to a lack of ceiling effects \[[@B1]\]. However, the use of postoperative opioids is associated with delayed recovery from anesthesia, postoperative nausea and vomiting (PONV), dizziness, pruritus, and respiratory depression \[[@B2][@B3][@B4]\]. In order to minimize the risk of opioid-related adverse effects and maintain effective pain control, the combined use of opioids with adjuvant analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) is a good option \[[@B5][@B6]\]. The adjuvant analgesics decrease opioid-related side effects with an opioid-sparing effect, and add a different analgesic action from opioids when used in combination.

Ketorolac tromethamine is a NSAID that inhibits cyclooxygenase (COX) activity in the arachidonic acid cascade and interferes with various inflammatory substances involved in the sensitization of nociceptors. NSAIDs are the most commonly used adjuvants of opioids for postoperative pain management \[[@B7][@B8]\]. Nefopam is a centrally acting non-opioid, non-steroidal analgesic that inhibits the reuptake of serotonin, norepinephrine, and dopamine \[[@B9]\]. Ketorolac and nefopam have no postoperative sedative and respiratory depression effects compared with opioids and they have unique analgesic mechanisms that are different from opioids. Furthermore, previous studies have established the analgesic efficacy and safety of ketorolac and nefopam in various surgical settings \[[@B10][@B11][@B12][@B13]\].

Many previous studies have demonstrated the analgesic efficacy and opioid-sparing effect of ketorolac and nefopam separately \[[@B14][@B15][@B16]\]. However, no study has compared the effects of ketorolac and nefopam as an adjuvant analgesic to opioid in postoperative PCA. The authors hypothesized that ketorolac and nefopam that were co-administered with fentanyl would show different analgesic efficacy and side effects because they have different action mechanisms. Therefore, we conducted this prospective, randomized, double-blinded study to compare the analgesic efficacy and side effects of ketorolac and nefopam that were co-administered with fentanyl via IV-PCA for postoperative analgesia after laparoscopic cholecystectomy.

Materials and Methods
=====================

This prospective, randomized, double-blind study was approved by the Institutional Review Board of the author\'s institution and registered with the WHO International Clinical Trials Registry Platform (KCT0001656). Written informed consent was obtained from all patients. One hundred and sixty patients, American Society of Anesthesiologists physical status I or II and aged 20 to 70 years, undergoing elective laparoscopic cholecystectomy were enrolled. Exclusion criteria were the use of analgesics, sedatives, or antidepressants within 48 h prior to surgery, alcohol or drug abuse, the presence of hepatic, renal, cardiopulmonary, hematologic, or psychological disorder, known intolerance or hypersensitivity to ketorolac, nefopam, and fentanyl, a history of motion sickness or PONV, or inability to understand the use of PCA. The four major risk factors of PONV are female gender, non-smoking, use of postoperative opioids, and prior history of motion sickness or PONV according to Apfel\'s simplified risk scoring system \[[@B17]\]. Because patients received fentanyl postoperatively and those who have a history of motion sickness or PONV were excluded, the enrolled patients in this study had one to three of PONV risk factors.

Subjects were randomly assigned by computer-generated random numbers to ketorolac (Group K) or nefopam (Group N) groups. We explained the use of the IV-PCA device (Accumate 1100®, Wooyoung Meditech, Seoul, Korea) and numerical rating scale (NRS; 0 = no pain, 10 = worst pain imaginable) for pain rating to each patient during the preanesthetic visit on the day before surgery. In addition, preoperative values of forced vital capacity (FVC) and forced expiratory volume in 1 sec (FEV1) were obtained with a portable pulmonary function test device (Contec® spirometer, Contec Medical System Co., Qinhuangdao, China).

No premedication was given for all patients. After placement of electrocardiogram, pulse oximetry, noninvasive blood pressure, bispectral index (BIS), and peripheral nerve stimulator, standard anesthetic regimens and techniques were used for all patients. Anesthesia was induced with 2--2.5 mg/kg propofol and 0.6--0.8 mg/kg rocuronium. The patients were manually ventilated via a face mask with sevoflurane 4.0 vol% in 50% oxygen until a train-of-four count of 0 in the peripheral nerve stimulator (TOF watch®, Organon Ltd., Dublin, Ireland). After orotracheal intubation, temperature was monitored at the nasopharynx and the patients were warmed by a forced-air warming system. Anesthesia was maintained with sevoflurane 1--4 vol% in 50% oxygen. Fresh gas flow rate was maintained at 3 L/min during the operation. End-tidal carbon dioxide partial pressure and BIS value were maintained at 30 to 35 mmHg and 40--60, respectively. Arterial blood pressure was kept within 20% of preanesthetic values by adjustment of inspired sevoflurane concentration. If a patient showed a mean arterial pressure of \< 60 mmHg despite decreasing sevoflurane concentration to 1 vol%, the patient received ephedrine. At the end of surgery, sevoflurane was discontinued and the patients were ventilated with a high fresh gas flow (\> 8 L/min) and received neostigmine and glycopyrrolate for reversal of neuromuscular blockade.

All patients were equipped with an IV PCA device for 48 hours. The analgesic solution contained fentanyl (Hana fentanyl citrate, Hana Pharm Co., Seoul, Korea) 600 µg and ketorolac (Trolac, Whanin Pharm Co., Seoul, Korea) 180 mg in Group K and fentanyl 600 µg and nefopam (Acupan, Phambio Korea, Seoul, Korea) 120 mg in Group N. Previous studies have reported that both nefopam 20 mg and ketorolac 30 mg have equianalgesic potency to 12 mg of morphine \[[@B18][@B19]\]. Therefore, the authors considered 180 mg of ketorolac and 120 mg of nefopam as equipotent. The total volume of analgesic solution was 120 ml. Patients were administered a loading dose of PCA (0.1 ml/kg analgesic solution) at skin closure for 20 min. No adjuncts for postoperative pain were allowed. Initial PCA settings were 1 ml/h background infusion, demand bolus dose of 3 ml, lockout interval of 7 min, and 6 times of 1 h limitation.

The primary endpoints of the study were postoperative analgesic consumption and pain intensity and the secondary endpoint was incidences of side effects. The postoperative analgesic solution consumption was recorded at postoperative 2, 6, 24, and 48 h. Postoperative pain intensities at rest and during forced expiration were evaluated by NRS during examination. The NRS pain scores were measured by an anesthesiologist who was blinded to the study groups to exclude inter-rater bias. The postoperative side effects of analgesics such as dizziness, sweating, hypotension, bradycardia, tachycardia, PONV, urinary retention, pruritus, somnolence, and respiratory depression were recorded. The postoperative recovery values of FVC and FEV1 were assessed at each time point. All patients were monitored in the postanesthesia care unit (PACU) for 2 h before discharge to surgical ward.

Statistical analysis
--------------------

A pilot study of 10 patients from Group K revealed analgesic solution consumption during the postoperative 48 h with an average of 100 ml and a standard deviation of 35 ml. For 48 h of cumulative postoperative analgesic solution consumption, we considered a difference of ≥ 20 ml to be clinically significantly. It was determined that 66 patients were required in each group to obtain a difference in mean analgesic solution consumption of 20 ml for an expected standard deviation of 35 ml at a significance level of 0.05 (α = 0.05) and a power of 90% (β = 0.10). To allow for attrition, the sample size was enlarged to 150.

Statistical analysis was performed with SigmaPlot 12.0 (Systat Software Inc. San Jose, USA). Data are presented as mean ± SD, or median (interquartile range). Patient characteristics and anesthesia time were analyzed with unpaired t-test or Chi-square test. Analgesic consumption was compared with unpaired t-test at each time point. The postoperative pain intensities measured by NRS within group and between groups at each time were analyzed using "one-way repeat measured ANOVA" rank sum test and Mann-Whitney rank sum test, respectively. Incidences of side effects were analyzed using Chi-square test. P values less than 0.05 were regarded as significant.

Results
=======

One hundred and fifty-one patients were allocated into groups and the subject flow diagram is shown in [Fig. 1](#F1){ref-type="fig"}. The two groups with remaining 142 patients completed the 48-h follow-up with adequate pain relief. The characteristics of the patients and anesthesia time were comparable between the groups ([Table 1](#T1){ref-type="table"}).

Analgesic consumptions at postoperative 2, 6, 24, and 48 h were similar between the groups ([Fig. 2](#F2){ref-type="fig"}). Cumulative postoperative analgesic consumptions at postoperative 48 h were similar between the groups (Group K: 93.4 ± 24.0 ml vs. Group N: 92.9 ± 26.1 ml, P = 0.906). There were no significant differences in NRS pain scores at rest and during deep breathing between the groups and the pain scores at rest were less than 4 for both groups ([Table 2](#T2){ref-type="table"}). Pulmonary function as determined by FVC and FEV1 decreased after operation and increased gradually over time. The 48-h postoperative values of FVC and FEV1 recovered to 90-91% and 93%, respectively, compared with the preoperative values of FVC and FEV1. The recovery of FVC and FEV1 showed no significant differences between the groups for each measurement ([Fig. 3](#F3){ref-type="fig"}).

PONV was the most common analgesic-related side effect in both groups. Overall, PONV incidence was higher in Group N compared with Group K (59% vs. 34%, P = 0.015) ([Table 3](#T3){ref-type="table"}). The PONV incidences were significantly higher in Group N than Group K in female (Group K: 20/35 patients \[63%\] vs. Group N: 29/33 patients \[88%\], P = 0.011) but, not in non-smoker patients (Group K: 16/34 patients \[47%\] vs. Group N: 16/26 patients \[62%\], P = 0.394). In groups K and N, the number of patients who experienced dizziness (1 vs. 3), tachycardia (1 vs. 2), hypotension (3 vs. 2), and bradycardia (1 vs. 1) were similar, and no patients experienced sweating, urinary retention, pruritus, somnolence, and respiratory depression.

Discussion
==========

This study examined the analgesic efficacy and side effects of ketorolac and nefopam that were co-administered with fentanyl via IV-PCA for postoperative analgesia. In the current study, there were no significant differences in postoperative analgesics consumption and pain intensity between the ketorolac-fentanyl and nefopam-fentanyl combinations. However, overall incidences of PONV for postoperative 48 h were significantly higher in Group N than in Group K (59% vs. 34%).

The use of nefopam or NSAIDs such as ketorolac for the treatment of postoperative pain is a common practice. However, NSAIDs and nefopam have been used as sole analgesics only for mild to moderate postoperative pain because they have an analgesic ceiling effect. Opioids are more effective than NSAIDs for moderate-to-severe acute pain \[[@B20][@B21]\]. Opioids are the cornerstone of postoperative pain management for severe pain, but they can cause PONV, pruritus, somnolence, and respiratory depression. Co-administration of adjuvant analgesics to an opioid regimen reduced opioid consumption, which could lead to a decrease in opioid-related side effects in the postoperative period. Cepeda et al. \[[@B21]\] demonstrated that the risk of side effects was increased by 1.3% for every 1-mg increase in morphine consumption. Also, they found that the addition of ketorolac to opioids decreased the risk of opioid-related side effects in the early postoperative period because of a considerable reduction in opioid requirements. Although the opioid-sparing effect of analgesics varied by surgery types and study design, the effects of nefopam and ketorolac seem to be similar and ranged from 20% to 50% \[[@B21][@B22]\].

Nefopam is a non-opioid, non-steroidal, centrally acting analgesic. Although the pharmacological mechanism of nefopam is unclear, its analgesic mechanisms involve the inhibition of reuptake of monoamine and action on α~2~-adrenergic and N-methyl-D-aspartate receptors \[[@B23][@B24]\]. Nefopam does not bind to opioid receptors and does not induce an anti-inflammatory effect such as NSAIDs \[[@B25]\]. Ketorolac is an IV injectable NSAID that has antipyretic, analgesic, and anti-inflammatory properties. It inhibits COX and hinders the activation of peripheral nociceptor system. Nefopam, ketorolac, and fentanyl have different inherent analgesic mechanisms. Multi-pharmacologic PCA regimens have the definite advantages in minimizing the risks of analgesic-related side effects and achieving more effective pain control. Therefore, nefopam and ketorolac could be good options for such purposes.

For the comparison of analgesic efficacy between nefopamfentanyl and ketorolac-fentanyl combinations, an equianalgesic dose was applied for both groups. Although no reports directly compared the analgesic potency between ketorolac and nefopam, the potency of nefopam 20 mg and ketorolac 30 mg were comparable with the potency of 12 mg morphine \[[@B18][@B19]\]. Therefore, the authors hypothesized that 20 mg of nefopam and 30 mg of ketorolac may have similar analgesic potency even though the relative analgesic potency could be different from pain intensity when compared with morphine. In the current study, the results showed almost similar cumulative postoperative analgesic consumptions at postoperative 48 h (93.4 ± 24.0 ml vs. 92.9 ± 26.1 ml) with similar pain intensities between the groups. It seems that nefopam 20 mg and ketorolac 30 mg are equianalgesic.

The mu opioid agonists, such as fentanyl and morphine, have similar side effects including nausea, dry mouth, constipation, vomiting, pruritus, sedation, and respiratory depression regardless. The most common postoperative side effects of opioid use are PONV. Ketorolac is known to be associated with several side effects related to the inhibition of COX, including gastrointestinal mucosal damage, platelet dysfunction, and renal toxicity. In comparison with fentanyl and ketorolac, nefopam does not cause sedation, respiratory depression, platelet dysfunction, or renal impairment, but it increases the incidence of sweating and tachycardia. In the current study, PONV incidences were 59% and 34% in Group N and K, respectively. The incidence of PONV in patients who underwent laparoscopic cholecystectomy with fentanyl-based postoperative pain control was 60--65% \[[@B26][@B27]\]. Although co-administration of nefopam could decrease fentanyl consumption, the nefopam-fentanyl combination did not reduce the incidence of PONV. Because the current study did not directly compare the nefopam-fentanyl combination versus fentanyl alone, caution is advised on the interpretation of our results. Yoon et al. \[[@B28]\] demonstrated that nefopam reduces the incidence of PONV compared with a combination of morphine and ketorolac in IV-PCA. Our study compared nefopamfentanyl with ketorolac-fentanyl combinations but, the study compared nefopam alone and morphine-ketorolac combination. Therefore, the discrepancy in the results could be due to the addition of an opioid. None of the patients showed a postoperative bleeding tendency in Groups K although physicians may be apprehensive about coagulopathy. Although previous studies have reported sweating (9--24%), tachycardia (12--21%), and hypertension (10--22%) as common side effects of nefopam, only two patients experienced tachycardia (3%), and none of them experienced sweating \[[@B29]\]. These low incidences may be due to the dilution and slow infusion of nefopam.

There are two limitations in the current study. First, incidences of analgesic-related side effects may have been underestimated. Although patients were observed continuously for the development of side effects in the PACU for the first 2 h, further evaluations were done at the surgical ward through medical records and questions to the patient at each measurement time point. Therefore, incidences of temporarily developed side effects, such as dizziness, sweating, hypotension, bradycardia, tachycardia, and somnolence may have been omitted. Second, although 73% of the subjects had two or three major PONV risk factors, they did not receive prophylactic antiemetics, which did not conform to PONV guidelines. However, patients were under close observation and received rescue antiemetic medications immediately when they showed vomiting or required rescue medications.

In conclusion, the current study demonstrated that the analgesic efficacies of ketorolac and nefopam, which were coadministered with fentanyl for postoperative pain management as adjuvant analgesics, were similar. However, PONV incidence was higher in the nefopam-fentanyl combination compared with that in the ketorolac-fentanyl combination. The incidences of other side effects were comparable between both combinations.
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![Study flow chart according to the CONSORT statement.](kjae-70-612-g001){#F1}

![There were no significant differences in analgesic consumptions at each measurement time point between both groups. Group K and N are the ketorolac-fentanyl and nefopam-fentanyl combinations, respectively.](kjae-70-612-g002){#F2}

![The recovery of forced vital capacity (FVC) and forced expiration volume in 1 sec (FEV1) showed no significant differences between the groups at each measurement time point. Group K and N are the ketorolac-fentanyl and nefopam-fentanyl combinations, respectively.](kjae-70-612-g003){#F3}

###### Patient Characteristics

![](kjae-70-612-i001)

                                       Group K (n = 76)   Group N (n = 66)   P values
  ------------------------------------ ------------------ ------------------ ----------
  Age (y)                              47.6 ± 10.3        45.7 ± 9.8         0.277
  Gender (F/M)                         35/41              33/33              0.763
  Height (cm)                          163.5 ± 8.1        164.4 ± 8.4        0.538
  Weight (kg)                          65.9 ± 11.9        69.1 ± 11.5        0.113
  Duration of anesthesia (min)         77.2 ± 15.9        79.6 ± 15.4        0.355
  Number of PONV risk factor (1/2/3)   20/21/35           19/14/33           0.676

Data are presented as mean ± SD and number of patients. Group K and N are the ketorolac-fentanyl and nefopam-fentanyl combinations, respectively.

PONV: postoperative nausea and vomiting.

###### Postoperative Pain Intensities Measured by the Numerical Rating Scale

![](kjae-70-612-i002)

         Group K (n = 76)   Group N (n = 66)   P values   
  ------ ------------------ ------------------ ---------- -------
  2 h    Rest               4 (3--5)           4 (3--5)   0.917
         Deep breath        5 (4--6.8)         5 (4--6)   0.827
  6 h    Rest               3 (2--4)           3 (2--4)   0.403
         Deep breath        3 (3--5)           4 (3--5)   0.426
  24 h   Rest               2 (1--3)           2 (1--3)   0.273
         Deep breath        3 (1.3--4)         3 (2--4)   0.191
  48 h   Rest               1 (1--2)           1 (1--2)   0.976
         Deep breath        2 (1--3)           2 (1--3)   0.955

Data are presented as median (interquartile range). Group K and N are the ketorolac-fentanyl and nefopam-fentanyl combinations, respectively.

###### Incidences of Postoperative Nausea and Vomiting and Use of Rescue Antiemetics
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                       Group K (n = 76)   Group N (n = 66)   P value        
  -------------------- ------------------ ------------------ -------------- -------
  0--2 h               Nausea             21 (28%)           26 (39%)       0.191
  Vomiting             4 (5%)             4 (6%)             0.873          
  Rescue medications   12 (16%)           10 (15%)           0.898          
  2--6 h               Nausea             16 (21%)           27 (41%)^\*^   0.017
  Vomiting             3 (4%)             2 (3%)             0.921          
  Rescue medications   7 (9%)             10 (15%)           0.407          
  6--24 h              Nausea             7 (9%)             13 (20%)       0.121
  Vomiting             1 (1%)             1 (2%)             0.540          
  Rescue medications   0 (0%)             5 (8%)^\*^         0.047          
  24--48 h             Nausea             4 (5%)             7 (11%)        0.383
  Vomiting             0 (0%)             1 (2%)             0.944          
  Rescue medications   0 (0%)             0 (0%)             NA             
  0--48 h              Nausea             26 (34%)           39 (59%)^\*^   0.015
  Vomiting             5 (7%)             7 (11%)            0.577          
  Rescue medications   14 (18%)           20 (30%)           0.145          

Data are presented as number of patients along with their percentage. Group K and N are the ketorolac-fentanyl and nefopam-fentanyl combinations, respectively. ^\*^P \< 0.05 compared with Group K.
